In breast cancer, MEK inhibition resulted in acute ERK activity loss and subsequent c-MYC degradation that induced expression and activation of PDGFRB, DDR2 and VEGFR272, an RTK combination found in patients 6 (PT) and 10 (M) of our dataset (Fig. 5). Here, MAP2K7 is linked to breast carcinoma.